-+ 0.00%
-+ 0.00%
-+ 0.00%

SpaceX (SPCX) Stock Shrugs Off Q3 Results As Profit Jumps

Simply Wall St·10/23/2026 23:26:20
Listen to the news

SpaceX stock closed Friday at US$147.50, up about 1.9% on the day, as traders gave a cautious nod to fresh Q3 2026 results. That move barely captures what just hit the tape. The company posted roughly US$14.6b in quarterly revenue and swung to a profit of about US$4.4b, turning a prior year loss into solid earnings power.

In the short term, the reaction looks modest. Over a longer period, the key development is the profit surge that now backs an aggressive multi-year buildout in launch, Starlink connectivity and super intelligence infrastructure.

Love the profit surge at Space Exploration Technologies but want a broader set of companies pairing strong earnings power with robust balance sheets? Scan the list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs. Q3 2025): US$14.58b vs. US$5.58b (very large year on year increase in quarterly revenue)
  • Net Income, Excl. Extra Items (Q3 2026 vs. Q3 2025): profit of US$4.40b vs. loss of US$1.05b (moved from loss to profit)
  • Basic EPS (Q3 2026 vs. Q3 2025): US$0.37 per share vs. a loss of US$0.36 per share (shift from loss per share to positive earnings per share)
  • Trailing 12 Month Revenue (TTM to Q3 2026 vs. TTM to Q3 2025): US$32.04b vs. US$10.39b (revenue grew 83.1% over the last year)

Tired of wading through dense earnings reports and spreadsheets? Get a clear visual overview of Space Exploration Technologies, with its profit profile and broader financial picture laid out in one easy dashboard via our company report for Space Exploration Technologies..

NasdaqGS:SPCX Trailing 12-Month Earnings & Revenue History as at Oct 2026
NasdaqGS:SPCX Trailing 12-Month Earnings & Revenue History as at Oct 2026

SpaceX bull case: Starship and xAI funding thesis tested

Optimists argued that public investors would bankroll loss making space and AI projects that private holders no longer wanted to carry.

"Rocket launches are profitable contracts from NASA, but they come with high costs. The development of the Starship rocket for flights to the Moon and Mars is a money pit."

Q3 results show Starship and Super Intelligence no longer only absorb cash. Space revenue reached US$1.8b and SI brought in US$7.6b, helping flip a prior loss into a US$4.4b profit. The IPO at US$135 and the current price around US$147 still left funding available for high capex projects without keeping the group in the red.

Bear case on structural losses versus new profitability print

Skeptics framed SpaceX as a perpetual cash sink where Mars ambitions and xAI spending would postpone profits indefinitely.

"The xAI artificial intelligence division requires massive investments in data centers and hardware, which is dragging SpaceX’s overall financial performance into the red."

Latest figures cut against that fear, at least for now. Super Intelligence is capital intensive, yet it generated US$7.6b of quarterly revenue alongside group net income of US$4.4b. The stock is up about 1.9% on the day and roughly flat over 30 days, so the move to profitability has not triggered a runaway bullish rerating yet.

One Narrative disagrees with today's price. → See where this Narrative says Space Exploration Technologies should trade.

Hunt Quiet Dislocations In Plain Sight

Space Exploration Technologies just shifted from heavy spending debate to fresh profitability based on recent results. The real opportunity is finding stocks that could be undervalued before the market corrects them.

  • Company 1 - 33% below our estimate - sells advanced GPU platforms that accelerate demanding AI workloads and specialized computing tasks.
  • Company 2 - 39% below our estimate - expands a once niche coconut drink into mainstream retail through branded packaging and private label partnerships.
  • Company 3 - 25% below our estimate - sells injectable treatments for weight loss and diabetes that influence demand across obesity and metabolic care.

That is three of the list. See all 27 potentially undervalued companies →